A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.

Stephen Lam ChanMartin SchulerYoon-Koo KangChia-Jui YenJulien EdelineSu Pin ChooChia-Chi LinTakuji OkusakaKarl-Heinz WeissTeresa MacarullaStéphane CattanJean-Frederic BlancKyung-Hun LeeMichela MaurShubham PantMasatoshi KudoEric AssenatAndrew X ZhuThomas YauHo Yeong LimJordi BruixAndreas GeierCarmen Guillén-PonceAngelica FasoloRichard S FinnJia FanArndt VogelShukui QinMarkus RiesterVasiliki KatsanouMonica ChaudhariTomoyuki KakizumeYi GuDiana Graus PortaAndrea MyersJean-Pierre Delord

Published in: Journal of experimental & clinical cancer research : CR (2022)

NCT02325739 .

Keyphrases

endothelial cells
open label
induced pluripotent stem cells
pluripotent stem cells
randomized controlled trial